HIV-related opportunistic infections

References

Key articles

Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Jul 2021 [internet publication].Full text

Aljohaney A, Amjadi K, Alvarez GG. A systematic review of the epidemiology, immunopathogenesis, diagnosis, and treatment of pleural TB in HIV-infected patients. Clin Dev Immunol. 2012;2012:842045.Full text  Abstract

Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother. 2007 Feb;13(1):1-7. Abstract

Aberg JA, Gallant JE, Ghanem KG, et al; Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jan;58(1):e1-34.Full text  Abstract

Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416.Full text  Abstract

Reference articles

1. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19.Full text  Abstract

2. Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Jul 2021 [internet publication].Full text

3. Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1993 Nov;148(5):1292-7. Abstract

4. Breen RA, Smith CJ, Cropley I, et al. Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS. 2005 Jul 22;19(11):1201-6. Abstract

5. B-Lajoie MR, Drouin O, Bartlett G, et al. Incidence and prevalence of opportunistic and other infections and the impact of antiretroviral therapy among HIV-infected children in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2016 Jun 15;62(12):1586-94.Full text  Abstract

6. Low A, Gavriilidis G, Larke N, et al. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2016 Jun 15;62(12):1595-603.Full text  Abstract

7. Hanna DB, Gupta LS, Jones LE, et al. AIDS-defining opportunistic illnesses in the HAART era in New York City. AIDS Care. 2007 Feb;19(2):264-72. Abstract

8. Lewden C, Salmon D, Morlat P, et al. Mortality 2000 study group. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005 Feb;34(1):121-30.Full text  Abstract

9. Bonnet F, Lewden C, May T, et al. Mortalite 2000 Study Group. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis. 2005;37(6-7):482-7. Abstract

10. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA. 1995 Jan 18;273(3):220-6. Abstract

11. Edwards D, Kirkpatrick CH. The immunology of mycobacterial diseases. Am Rev Respir Dis. 1986 Nov;134(5):1062-71. Abstract

12. Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis. 1992 Jul;15(1):1-10. Abstract

13. Drew WL. Diagnosis of cytomegalovirus infection. Rev Infect Dis. 1988 Jul-Aug;10(suppl 3):S468-76. Abstract

14. Stringer JR, Beard CB, Miller RF, et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002 Sep;8(9):891-6.Full text  Abstract

15. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004 Jun 12;363(9425):1965-76. Abstract

16. Luft BJ, Chua A. Central nervous system toxoplasmosis in HIV pathogenesis, diagnosis, and therapy. Curr Infect Dis Rep. 2000 Aug;2(4):358-62. Abstract

17. Nosanchuk JD, Shoham S, Fries BC, et al. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med. 2000 Feb 1;132(3):205-8. Abstract

18. Sorvillo F, Beall G, Turner PA, et al. Incidence and factors associated with extrapulmonary cryptococcosis among persons with HIV infection in Los Angeles County. AIDS. 1997 Apr;11(5):673-9. Abstract

19. Hellerstein MK, McCune JM. T cell turnover in HIV-1 disease. Immunity. 1997 Nov;7(5):583-9.Full text  Abstract

20. Liu X, Liu H, Guo Z, et al. Association of asymptomatic oral candidal carriage, oral candidiasis and CD4 lymphocyte count in HIV-positive patients in China. Oral Dis. 2006 Jan;12(1):41-4. Abstract

21. Gottfredsson M, Cox GM, Indridason OS, et al. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis. 1999 Aug;180(2):534-7.Full text  Abstract

22. Yeh CK, Fox PC, Ship JA, et al. Oral defense mechanisms are impaired early in HIV-1 infected patients. J Acquir Immune Defic Syndr. 1988;1(4):361-6. Abstract

23. Meltzer MS, Skillman DR, Gomatos PJ, et al. Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu Rev Immunol. 1990;8:169-94. Abstract

24. Gray JR, Rabeneck L. Atypical mycobacterial infection of the gastrointestinal tract in AIDS patients. Am J Gastroenterol. 1989 Dec;84(12):1521-4. Abstract

25. Stacey AR. Isolation of Mycobacterium avium-intracellulare-scrofulaceum complex from faeces of patients with AIDS. Br Med J (Clin Res Ed). 1986 Nov 8;293(6556):1194.Full text  Abstract

26. Gerna G, Parea M, Percivalle E, et al. Human cytomegalovirus viraemia in HIV-1-seropositive patients at various clinical stages of infection. AIDS. 1990 Oct;4(10):1027-31. Abstract

27. Gigliotti F, Wright TW. Immunopathogenesis of Pneumocystis carinii pneumonia. Expert Rev Mol Med. 2005 Nov 14;7(26):1-16. Abstract

28. Subauste CS, Remington JS. Immunity to Toxoplasma gondii. Curr Opin Immunol. 1993 Aug;5(4):532-7. Abstract

29. Yap GS, Scharton-Kersten T, Charest H, et al. Decreased resistance of TNF receptor p55- and p75-deficient mice to chronic toxoplasmosis despite normal activation of inducible nitric oxide synthase in vivo. J Immunol. 1998 Feb 1;160(3):1340-5.Full text  Abstract

30. Chen XM, Keithly JS, Paya CV, et al. Cryptosporidiosis. N Engl J Med. 2002 May 30;346(22):1723-31. Abstract

31. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005 Jan 15;191(2):150-8.Full text  Abstract

32. Havlir DV, Getahun H, Sanne I, et al. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008 Jul 23;300(4):423-30. Abstract

33. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002 Jun 15;359(9323):2059-64. Abstract

34. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990 Jan 18;322(3):161-5. Abstract

35. Grant IH, Gold JW, Rosenblum M, et al. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS. 1990 Jun;4(6):519-21. Abstract

36. Pinner RW, Hajjeh RA, Powderly WG. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis. 1995 Aug;21(suppl 1):S103-7. Abstract

37. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis. 1991 Nov-Dec;13(6):1163-9. Abstract

38. Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis. 1992 Jun;165(6):1082-5. Abstract

39. Sax PE. Opportunistic infections in HIV disease: down but not out. Infect Dis Clin North Am. 2001 Jun;15(2):433-55. Abstract

40. Jackson JB, Erice A, Englund JA, et al. Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1. Transfusion. 1988 Mar-Apr;28(2):187-9. Abstract

41. Lin RY, Goodhart PT. Population characteristics of tuberculosis in an HIV/AIDS registry from an East Harlem Hospital. N Y State J Med. 1991 Jun;91(6):239-42. Abstract

42. Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med. 2008 Feb 1;177(3):348-55.Full text  Abstract

43. Selwyn PA, Sckell BM, Alcabes P, et al. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992 Jul 22-29;268(4):504-9. Abstract

44. Soysa NS, Ellepola AN. The impact of cigarette/tobacco smoking on oral candidosis: an overview. Oral Dis. 2005 Sep;11(5):268-73. Abstract

45. Slavinsky J 3rd, Myers T, Swoboda RK, et al. Th1/Th2 cytokine profiles in saliva of HIV-positive smokers with oropharyngeal candidiasis. Oral Microbiol Immunol. 2002 Feb;17(1):38-43. Abstract

46. Carr A, Tindall B, Penny R, et al. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS. 1992 Feb;6(2):165-71. Abstract

47. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim/sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. 1995 May 15;122(10):755-61. Abstract

48. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Suppl. 1989 Jun 16;38(5):1-9.Full text  Abstract

49. Trikalinos TA, Ioannidis JP. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. Clin Infect Dis. 2001 Dec 1;33(11):1901-9.Full text  Abstract

50. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med. 2000 May 11;342(19):1416-29. Abstract

51. Furrer H, Opravil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet. 2000 Jun 24;355(9222):2217-8. Abstract

52. Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020 Feb 14;69(1):1-11.Full text  Abstract

53. World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Mar 2020 [internet publication].Full text

54. Centers for Disease Control. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC Recommendations - United States, 2001. MMWR Morb Mortal Wkly Rep. 2001 Aug 31;50(34):733-5.Full text  Abstract

55. Greenberg SD, Frager D, Suster B, et al. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology. 1994 Oct;193(1):115-9. Abstract

56. Kennedy DJ, Lewis WP, Barnes PF. Yield of bronchoscopy for the diagnosis of tuberculosis in patients with human immunodeficiency virus infection. Chest. 1992 Oct;102(4):1040-4. Abstract

57. Pepper T, Joseph P, Mwenya C, et al. Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. Int J Tuberc Lung Dis. 2008 Apr;12(4):397-403.Full text  Abstract

58. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection 2021 update. Jul 2021 [internet publication].Full text

59. Aljohaney A, Amjadi K, Alvarez GG. A systematic review of the epidemiology, immunopathogenesis, diagnosis, and treatment of pleural TB in HIV-infected patients. Clin Dev Immunol. 2012;2012:842045.Full text  Abstract

60. Baba K, Hoosen AA, Langeland N, et al. Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. PLoS One. 2008 Jul 30;3(7):e2788.Full text  Abstract

61. Torok ME, Chau TT, Mai PP, et al. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS One. 2008 Mar 19;3(3):e1772.Full text  Abstract

62. Aaron L, Saadoun D, Calatroni, I, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect. 2004 May;10(5):388-98.Full text  Abstract

63. Mistry BJ, Kala UK. Palatial erosion caused by Mycobacterium Avium complex in a human immunodeficiency virus infected child. Pediatr Infect Dis J. 2007 Jun;26(6):546-8. Abstract

64. Blumenthal DR, Zucker JR, Hawkins CC. Mycobacterium avium complex-induced septic arthritis and osteomyelitis in a patient with the acquired immunodeficiency syndrome. Arthritis Rheum. 1990 May;33(5):757-8.Full text  Abstract

65. Cappell MS, Gupta A. Gastrointestinal hemorrhage due to gastrointestinal Mycobacterium avium intracellulare or esophageal candidiasis in patients with the acquired immunodeficiency syndrome. Am J Gastroenterol. 1992 Feb;87(2):224-9. Abstract

66. von Reyn CF, Hennigan S, Niemczyk S, et al. Effect of delays in processing on the survival of Mycobacterium avium-M. intracellulare in the isolator blood culture system. J Clin Microbiol. 1991 Jun;29(6):1211-4.Full text  Abstract

67. Chin D, Hopewell PC, Yajko DM, et al. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. J Infect Dis. 1994 Feb;169(2):289-95. Abstract

68. Koh DM, Burn PR, Mathews G, et al. Abdominal computed tomographic findings of Mycobacterium tuberculosis and Mycobacterium avium intracellulare infection in HIV seropositive patients. Can Assoc Radiol J. 2003 Feb;54(1):45-50. Abstract

69. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984 May;100(5):663-71. Abstract

70. Mascarenhas DA, Vasudevan VP, Vaidya KP. Pneumocystis carinii pneumonia. Rare cause of hemoptysis. Chest. 1991 Jan;99(1):251-3. Abstract

71. Hopewell PC, Luce JM. Pulmonary involvement in the acquired immunodeficiency syndrome. Chest. 1985 Jan;87(1):104-12. Abstract

72. Huang L, Stansell J, Osmond D, et al. Performance of an algorithm to detect Pneumocystis carinii pneumonia in symptomatic HIV-infected persons. Chest. 1999 Apr;115(4):1025-32. Abstract

73. Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Am Rev Respir Dis. 1988 Apr;137(4):796-800. Abstract

74. Smith DE, McLuckie A, Wyatt J, et al. Severe exercise hypoxaemia with normal or near normal x-rays: a feature of Pneumocystis carinii infection. Lancet. 1988 Nov 5;2(8619):1049-51. Abstract

75. Cruciani M, Marcati P, Malena M, et al. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J. 2002 Oct;20(4):982-9.Full text  Abstract

76. DeLorenzo LJ, Huang CT, Maguire GP, et al. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest. 1987 Mar;91(3):323-7. Abstract

77. Abd AG, Nierman DM, Ilowite JS, et al. Bilateral upper lobe Pneumocystis carinii pneumonia in a patient receiving inhaled pentamidine prophylaxis. Chest. 1988 Aug;94(2):329-31. Abstract

78. Vermeij CG, van der Pijl JW, Brahim JJ, et al. High-resolution computed tomography scan in Pneumocystis carinii pneumonia. Chest. 1995 Jan;107(1):293.Full text  Abstract

79. Coleman DL, Dodek PM, Luce JM, et al. Diagnostic utility of fiberoptic bronchoscopy in patients with Pneumocystis carinii pneumonia and the acquired immune deficiency syndrome. Am Rev Respir Dis. 1983 Nov;128(5):795-9. Abstract

80. Khalkhali I, Mena I, Rauh DA, et al. 111-indium-DTPA-IgG lung imaging in patients with pulmonary and HIV infection. Chest. 1995 May;107(5):1336-41. Abstract

81. Kroe DM, Kirsch CM, Jensen WA. Diagnostic strategies for Pneumocystis carinii pneumonia. Semin Respir Infect. 1997 Jun;12(2):70-8. Abstract

82. Smego RA Jr, Orlovic D, Wadula, J. An algorithmic approach to intracranial mass lesions in HIV/AIDS. Int J STD AIDS. 2006 Apr;17(4):271-6. Abstract

83. Levy RM, Mills CM, Posin JP, et al. The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study. J Acquir Immune Defic Syndr. 1990;3(5):461-71. Abstract

84. Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1993 Sep 30;329(14):995-1000.Full text  Abstract

85. Lorberboym M, Wallach F, Estok L, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med. 1998 Aug;39(8):1366-9.Full text  Abstract

86. Love C, Tomas MB, Tronco GG, et al. FDG PET of infection and inflammation. Radiographics. 2005 Sep-Oct;25(5):1357-68.Full text  Abstract

87. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-83.Full text  Abstract

88. Kalayjian RC, Cohen ML, Bonomo RA, et al. Cytomegalovirus ventriculoencephalitis in AIDS. A syndrome with distinct clinical and pathologic features. Medicine (Baltimore). 1993 Mar;72(2):67-77. Abstract

89. Meiselman MS, Cello JP, Margaretten W. Cytomegalovirus colitis. Report of the clinical, endoscopic, and pathologic findings in two patients with the acquired immune deficiency syndrome. Gastroenterology. 1985 Jan;88(1 Pt 1):171-5. Abstract

90. Brantsaeter AB, Holberg-Petersen M, Jeansson S, et al. CMV quantitative PCR in the diagnosis of CMV disease in patients with HIV-infection - a retrospective autopsy based study. BMC Infect Dis. 2007 Nov 6;7:127.Full text  Abstract

91. Bianchi M, Robles AM, Vitale R, et al. The usefulness of blood culture in diagnosing HIV-related systemic mycoses: evaluation of a manual lysis centrifugation method. Med Mycol. 2000 Feb;38(1):77-80.Full text  Abstract

92. Tavitian A, Raufman JP, Rosenthal LE. Oral candidiasis as a marker for esophageal candidiasis in the acquired immunodeficiency syndrome. Ann Intern Med. 1986 Jan;104(1):54-5. Abstract

93. Thom K, Forrest G. Gastrointestinal infections in immunocompromised hosts. Curr Opin Gastroenterol. 2006 Jan;22(1):18-23. Abstract

94. Nokta M. Oral manifestations associated with HIV infection. Curr HIV/AIDS Rep. 2008 Feb;5(1):5-12. Abstract

95. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999 Feb 4;340(5):367-73. Abstract

96. Armstrong WS, Katz JT, Kazanjian PH. Human immunodeficiency virus-associated fever of unknown origin: a study of 70 patients in the United States and review. Clin Infect Dis. 1999 Feb;28(2):341-5.Full text  Abstract

97. Havlik JA Jr, Horsburgh CR Jr, Metchock B, et al. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis. 1992 Mar;165(3):577-80. Abstract

98. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother. 2007 Feb;13(1):1-7. Abstract

99. Mayo J, Collazos J, Martinez E. Fever of unknown origin in the HIV-infected patient: new scenario for an old problem. Scand J Infect Dis. 1997;29(4):327-36. Abstract

100. Navia BA, Petito CK, Gold JW, et al. Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: clinical and neuropathological findings in 27 patients. Ann Neurol. 1986 Mar;19(3):224-38. Abstract

101. Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull. 2005 Apr 18;72:99-118.Full text  Abstract

102. Donald PR, Schoeman JF. Tuberculous meningitis. N Engl J Med. 2004 Oct 21;351(17):1719-20. Abstract

103. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. 1998 Jan 24;351(9098):252-5. Abstract

104. Jabs DA. AIDS and ophthalmology, 2008. Arch Ophthalmol. 2008 Aug;126(8):1143-6. Abstract

105. Rabaud C, May T, Amiel C, et al. Extracerebral toxoplasmosis in patients infected with HIV. A French national survey. Medicine (Baltimore). 1994 Nov;73(6):306-14. Abstract

106. Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis. 1997 Aug;25(2):242-6. Abstract

107. Jost KC Jr, Dunbar DF, Barth SS, et al. Identification of Mycobacterium tuberculosis and M. avium complex directly from smear-positive sputum specimens and BACTEC 12B cultures by high-performance liquid chromatography with fluorescence detection and computer-driven pattern recognition models. J Clin Microbiol. 1995 May;33(5):1270-7.Full text  Abstract

108. Aderaye G, Woldeamanuel Y, Asrat D, et al. Evaluation of Toluidine Blue O staining for the diagnosis of Pneumocystis jiroveci in expectorated sputum sample and bronchoalveolar lavage from HIV-infected patients in a tertiary care referral center in Ethiopia. Infection. 2008 Jun;36(3):237-43. Abstract

109. Yagupsky P, Menegus MA. Cumulative positivity rates of multiple blood cultures for Mycobacterium avium-intracellulare and Cryptococcus neoformans in patients with the acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1990 Sep;114(9):923-5. Abstract

110. Stover DE, White DA, Romano PA, et al. Diagnosis of pulmonary disease in acquired immune deficiency syndrome (AIDS). Role of bronchoscopy and bronchoalveolar lavage. Am Rev Respir Dis. 1984 Oct;130(4):659-62. Abstract

111. Reina J, Riera M, Bestard X, et al. Virologic analysis of 1,000 blood samples processed for cytomegalovirus isolation (viremia) and pp65 antigenemia in immunodepressed patients [in Spanish]. Med Clin (Barc). 1998 Mar 7;110(8):281-4. Abstract

112. Powderly WG, Mayer KH, Perfect JR. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1405-12. Abstract

113. Skiest DJ, Crosby C. CMV pp65 antigen testing is of limited utility in the diagnosis of concomitant CMV disease in HIV-infected patients in the HAART era. J Clin Virol. 2003 Oct;28(2):203-13. Abstract

114. Colombo FA, Vidal JE, Penalva de Oliveira AC, et al. Diagnosis of cerebral toxoplasmosis in AIDS patients in Brazil: importance of molecular and immunological methods using peripheral blood samples. J Clin Microbiol. 2005 Oct;43(10):5044-7.Full text  Abstract

115. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis. 2000 Jan;30(1):47-54.Full text  Abstract

116. Dupon M, Cazenave J, Pellegrin JL, et al. Detection of Toxoplasma gondii by PCR and tissue culture in cerebrospinal fluid and blood of human immunodeficiency virus-seropositive patients. J Clin Microbiol. 1995 Sep;33(9):2421-6.Full text  Abstract

117. Hammarin AL, Bogdanovic G, Svedhem V, et al. Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy. J Clin Microbiol. 1996 Dec;34(12):2929-32.Full text  Abstract

118. Akpek G, Lee SM, Gagnon DR, et al. Bone marrow aspiration, biopsy, and culture in the evaluation of HIV-infected patients for invasive mycobacteria and histoplasma infections. Am J Hematol. 2001 Jun;67(2):100-6.Full text  Abstract

119. Tarantino L, Giorgio A, de Stefano G, et al. Disseminated mycobacterial infection in AIDS patients: abdominal US features and value of fine-needle aspiration biopsy of lymph nodes and spleen. Abdom Imaging. 2003 Sep-Oct;28(5):602-8. Abstract

120. Steininger C, Puchhammer-Stockl E, Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J Clin Virol. 2006 Sep;37(1):1-9. Abstract

121. Gascon P, Sathe SS, Rameshwar P. Impaired erythropoiesis in the acquired immunodeficiency syndrome with disseminated Mycobacterium avium complex. Am J Med. 1993 Jan;94(1):41-8. Abstract

122. Horsburgh CR Jr, Metchock B, Gordon SM, et al. Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease. J Infect Dis. 1994 Sep;170(3):573-7. Abstract

123. Graviss EA, Vanden Heuvel EA, Lacke CE, et al. Clinical prediction model for differentiation of disseminated Histoplasma capsulatum and Mycobacterium avium complex infections in febrile patients with AIDS. J Acquir Immune Defic Syndr. 2000 May 1;24(1):30-6. Abstract

124. Chang YG, Chen PJ, Hung CC, et al. Opportunistic hepatic infections in AIDS patients with fever of unknown origin. J Formos Med Assoc. 1999 Jan;98(1):5-10. Abstract

125. Salomon N, Perlman DC. Cytomegalovirus pneumonia. Semin Respir Infect. 1999 Dec;14(4):353-8. Abstract

126. Kuhlman JE. Pneumocystic infections: the radiologist's perspective. Radiology. 1996 Mar;198(3):623-35. Abstract

127. Fee MJ, Oo MM, Gabayan AE, et al. Abdominal tuberculosis in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1995 Apr;20(4):938-44. Abstract

128. Pantongrag-Brown L, Krebs TL, Daly BD, et al. Frequency of abdominal CT findings in AIDS patients with M. avium complex bacteraemia. Clin Radiol. 1998 Nov;53(11):816-9. Abstract

129. Hidalgo A, Falco V, Mauleon S, et al. Accuracy of high-resolution CT in distinguishing between Pneumocystis carinii pneumonia and non-Pneumocystis carinii pneumonia in AIDS patients. Eur Radiol. 2003 May;13(5):1179-84. Abstract

130. Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol. 1997 Oct;169(4):967-75.Full text  Abstract

131. McGuinness G. Changing trends in the pulmonary manifestations of AIDS. Radiol Clin North Am. 1997 Sep;35(5):1029-82. Abstract

132. Olatinwo TF, Herbowy MT, Hewitt RG. Toxoplasmic encephalitis and primary lymphoma of the brain-the shift in epidemiology: a case series and review of the literature. AIDS Read. 2001 Sep;11(9):444-9. Abstract

133. Rene E, Marche C, Chevalier T, et al. Cytomegalovirus colitis in patients with acquired immunodeficiency syndrome. Dig Dis Sci. 1988 Jun;33(6):741-50. Abstract

134. Wilcox CM, Schwartz DA. Endoscopic-pathologic correlates of Candida esophagitis in acquired immunodeficiency syndrome. Dig Dis Sci. 1996 Jul;41(7):1337-45. Abstract

135. Davis JL, Fei M, Huang L. Respiratory infection complicating HIV infection. Curr Opin Infect Dis. 2008 Apr;21(2):184-90.Full text  Abstract

136. Aberg JA, Gallant JE, Ghanem KG, et al; Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jan;58(1):e1-34.Full text  Abstract

137. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection: United States, 2014. MMWR Recomm Rep. 2014 Apr 11;63(RR-03):1-10.Full text  Abstract

138. World Health Organization. Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children. Mar 2018 [internet publication].Full text

139. Zolopa A, Andersen J, Komarow L, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575.Full text  Abstract

140. El-Sadr WMG, Grund B, Neuhaus J, et al; SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008 Sep 2;149(5):289-99. Abstract

141. British HIV Association. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). Aug 2016 [internet publication].Full text

142. Munseri PJ, Talbot EA, Mtei L, et al. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis. 2008 Sep;12(9):1037-41.Full text  Abstract

143. Telzak EE, Chirgwin KD, Nelson ET, et al. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Int J Tuberc Lung Dis. 1999 Apr;3(4):337-43.Full text  Abstract

144. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. Jun 2013 [internet publication].Full text

145. Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015 Jul 7;163(1):32-9. Abstract

146. Ward TT, Rimland D, Kauffman C, et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Clin Infect Dis. 1998 Nov;27(5):1278-85. Abstract

147. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med. 2000 Apr 13;342(15):1085-92.Full text  Abstract

148. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416.Full text  Abstract

149. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim/sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis. 1994 Oct;170(4):912-7. Abstract

150. Morris A, Wachter RM, Luce J, et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS. 2003 Jan 3;17(1):73-80.Full text  Abstract

151. Benfield T, Atzori C, Miller RF, et al. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr. 2008 May 1;48(1):63-7.Full text  Abstract

152. Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;(4):CD006150.Full text  Abstract

153. Dworkin MS, Hanson DL, Navin TR. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis. 2001 May 1;183(9):1409-12.Full text  Abstract

154. Van Delden C, Hirschel B. Folinic acid supplements to pyrimethamine-sulfadiazine for Toxoplasma encephalitis are associated with better outcome. J Infect Dis. 1996 May;173(5):1294-5. Abstract

155. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010 Feb 1;50(3):291-322.Full text  Abstract

156. van der Horst C, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997 Jul 3;337(1):15-21.Full text  Abstract

157. European Medicines Agency. Flucytosine: updated recommendations for the use in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. Jun 2020 [internet publication].Full text

158. Medicines and Healthcare products Regulatory Agency. Flucytosine (Ancotil): new contraindication in patients with DPD deficiency. Oct 2020 [internet publication].Full text

159. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999 Feb;28(2):291-6.Full text  Abstract

160. Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005 Apr 1;40(7):1049-52.Full text  Abstract

161. Larsen RA. Editorial response: a comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999 Feb;28(2):297-8.Full text  Abstract

162. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis. 2003 May 15;36(10):1329-31.Full text  Abstract

163. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis. 1993 Dec;168(6):1506-9. Abstract

164. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.Full text  Abstract

165. Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. JAMA. 2004;291:938.

166. Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1998 Jun;42(6):1346-9.Full text  Abstract

167. Hamza OJ, Matee MI, Bruggemann RJ, et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis. 2008 Nov 15;47(10):1270-6.Full text  Abstract

168. Wang F, Langley R, Gulten G, et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.Full text  Abstract

169. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis. 2006 Oct 15;43(8):1060-8.Full text  Abstract

170. Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012 Jun 1;26(9):1105-13.Full text  Abstract

171. Vadlapudi AD, Vadlapatla RK, Mitra AK. Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents. Recent Pat Antiinfect Drug Discov. 2012 Apr;7(1):8-18.Full text  Abstract

172. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services. Mar 2021 [internet publication].Full text

173. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel. JAMA. 2020 Oct 27;324(16):1651-69.Full text  Abstract

174. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020 Jul 7;56(1):2000535.Full text  Abstract

175. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - second edition. Jun 2016 [internet publication].Full text

176. European AIDS Clinical Society. Guidelines version 10.1. Oct 2020 [internet publication].Full text

177. Raviglione MC. Facing extensively drug-resistant tuberculosis-a hope and a challenge. N Engl J Med. 2008 Aug 7;359(6):636-8.Full text  Abstract

178. Driver CR, Munsiff SS, Li J, et al. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis. 2001 Nov 15;33(10):1762-9.Full text  Abstract

179. Corti M, Palmero D. Mycobacterium avium complex infection in HIV/AIDS patients. Expert Rev Anti Infect Ther. 2008 Jun;6(3):351-63. Abstract

180. Vidal JE, Hernandez AV, de Oliveira AC, et al. Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era. AIDS Patient Care STDS. 2005 Oct;19(10):626-34. Abstract

181. Hoffmann C, Ernst M, Meyer P, et al. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. Clin Microbiol Infect. 2007 May;13(5):510-5.Full text  Abstract

182. Signorini L, Gulletta M, Coppini D, et al. Fatal disseminated toxoplasmosis during primary HIV infection. Curr HIV Res. 2007 Mar;5(2):273-4. Abstract

183. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008 Jun 1;46(11):1694-701.Full text  Abstract

184. Kedhar DR, Jabs DA. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes. 2007 Dec;14(3):66-71. Abstract

185. Launay O, Lortholary O, Bouges-Michel C, et al. Candidemia: a nosocomial complication in adults with late-stage AIDS. Clin Infect Dis. 1998 May;26(5):1134-41. Abstract

186. Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis. 2005 Nov 15;41(10):1483-97.Full text  Abstract

187. Murdoch DM, Venter WD, Van Rie A, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007 May 8;4:9.Full text  Abstract

188. Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010 Apr;10(4):251-61.Full text  Abstract

189. Grant PM, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One. 2010 Jul 1;5(7):e11416.Full text  Abstract

190. Accorinti M, Pirraglia MP, Corradi R, et al. Changing patterns of ocular manifestations in HIV seropositive patients treated with HAART. Eur J Ophthalmol. 2006 Sep-Oct;16(5):728-32. Abstract

191. Thorne JE, Jabs DA, Kempen JH, et al. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006 Aug;113(8):1432-40. Abstract

192. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003 Jun 20;52(RR-11):1-77.Full text  Abstract

193. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology. 2004 Dec;111(12):2224-31. Abstract

194. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology. 2004 Dec;111(12):2232-9. Abstract

195. National Tuberculosis Controllers Association, Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005 Dec 16;54(RR-15):1-47.Full text  Abstract

196. Miro JM, Lopez JC, Podzamczer D, et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis. 2006 Jul 1;43(1):79-89.Full text  Abstract

197. Walmsley SL, Raboud J, Angel JB, et al. Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis. HIV Clin Trials. 2006 Jan-Feb;7(1):1-9. Abstract

198. Soriano V, Dona C, Rodriguez-Rosado R, et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2000 Mar 10;14(4):383-6. Abstract

Use of this content is subject to our disclaimer